Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Real-World study tests nemolizumab for chronic itch condition

NCT ID NCT06988618

Symptom relief Sponsor: Galderma R&D Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 2 times

Summary

This study looks at how well the drug nemolizumab works for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. Researchers will track 600 participants over 6 months in real-world clinics, measuring itch severity and skin lesion improvement. The goal is to see if the drug helps control symptoms in everyday practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The clinical decision for treatment with nemolizumab has to be made by the physicians independently of the participation in this NIS and prior to the informed consent process. Participants greater than or equal to (\>=) 18 years of age will be eligible for the trial.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants who, according to the treating physician's decision and in line with the local package label, are newly initiated on nemolizumab (Nemluvio®) for the treatment of PN. * Participants greater than or equal to (\>=) 18 years of age. * Participants who signed the written informed consent form (ICF). Exclusion Criteria: * Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label; * Participants who received treatment with a drug under clinical development/ investigation within 3 months prior to baseline. * Participants who received nemolizumab previously. * Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prurigo nodularis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prurigo nodularis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prurigo nodularis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    51 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Galderma Investigation Site # 6367

    RECRUITING

    Rostock, Mecklenburg-Vorpommern, 18057, Germany

  • Galderma Investigational Site # 5437

    RECRUITING

    Kiel, Schleswig-Holstein, 24105, Germany

  • Galderma Investigational Site # 6369

    RECRUITING

    Erlangen, Bavaria, 91054, Germany

  • Galderma Investigational Site # 6370

    NOT_YET_RECRUITING

    Haslach, 77716, Germany

  • Galderma Investigational Site # 6371

    RECRUITING

    Oberursel, 61440, Germany

  • Galderma Investigational Site # 6373

    RECRUITING

    Mainz, 55128, Germany

  • Galderma Investigational Site # 6374

    RECRUITING

    Karlsruhe, Baden-Wurttemberg, 76133, Germany

  • Galderma Investigational Site # 6384

    RECRUITING

    Koblenz, 56068, Germany

  • Galderma Investigational Site # 6385

    RECRUITING

    Berlin, 10117, Germany

  • Galderma Investigational Site # 6386

    RECRUITING

    Bielefeld, 33647, Germany

  • Galderma Investigational Site # 6387

    RECRUITING

    Ahaus, 48683, Germany

  • Galderma Investigational Site # 6836

    RECRUITING

    Fountain Valley, California, 92708-3701, United States

  • Galderma Investigational Site # 7051

    RECRUITING

    New York, New York, 10023, United States

  • Galderma Investigational Site # 7052

    RECRUITING

    East Syracuse, New York, 13057, United States

  • Galderma Investigational Site # 7053

    RECRUITING

    Waterford, Michigan, 48328, United States

  • Galderma Investigational Site # 7055

    RECRUITING

    Portsmouth, New Hampshire, 03801-7156, United States

  • Galderma Investigational Site # 7056

    RECRUITING

    New York, New York, 10012-1354, United States

  • Galderma Investigational Site # 7057

    RECRUITING

    Lee's Summit, Missouri, 64064, United States

  • Galderma Investigational Site # 7058

    NOT_YET_RECRUITING

    Chicago, Illinois, 60641, United States

  • Galderma Investigational Site # 7059

    RECRUITING

    Fairfield, Connecticut, 06824, United States

  • Galderma Investigational Site # 7060

    RECRUITING

    Phoenix, Arizona, 85008-3884, United States

  • Galderma Investigational Site # 7061

    RECRUITING

    Castle Rock, Colorado, 80109-8034, United States

  • Galderma Investigational Site # 7062

    RECRUITING

    Edinburg, Texas, 78539-4660, United States

  • Galderma Investigational Site # 7063

    RECRUITING

    Cutler Bay, Florida, 33157, United States

  • Galderma Investigational Site # 7064

    RECRUITING

    Santa Monica, California, 90404-2216, United States

  • Galderma Investigational Site # 7065

    RECRUITING

    Brighton, Massachusetts, 02135, United States

  • Galderma Investigational Site # 7066

    RECRUITING

    Auburn Hills, Michigan, 48326-3396, United States

  • Galderma Investigational Site # 7067

    RECRUITING

    Tucson, Arizona, 85718, United States

  • Galderma Investigational Site # 7068

    RECRUITING

    Rockville, Maryland, 20850-6243, United States

  • Galderma Investigational Site # 7069

    RECRUITING

    Sugar Land, Texas, 77478-3842, United States

  • Galderma Investigational Site # 7070

    RECRUITING

    North Miami Beach, Florida, 33162-4708, United States

  • Galderma Investigational Site # 7071

    RECRUITING

    Caledonia, Michigan, 49316-7478, United States

  • Galderma Investigational Site # 7072

    RECRUITING

    Troy, Michigan, 48084-5260, United States

  • Galderma Investigational Site # 7074

    RECRUITING

    Corona, California, 92882, United States

  • Galderma Investigational Site # 7076

    RECRUITING

    St Louis, Missouri, 63141-7068, United States

  • Galderma Investigational Site # 7077

    RECRUITING

    Phoenix, Arizona, 85006-2754, United States

  • Galderma Investigational Site # 7078

    RECRUITING

    Miami, Florida, 33173, United States

  • Galderma Investigational Site # 7079

    RECRUITING

    Vienna, Virginia, 22182, United States

  • Galderma Investigational Site # 7080

    RECRUITING

    Auburn, New York, 13021, United States

  • Galderma Investigational Site # 7081

    RECRUITING

    Dayton, Ohio, 45414-2799, United States

  • Galderma Investigational Site # 7087

    RECRUITING

    Coral Gables, Florida, 33134, United States

  • Galderma Investigational Site # 7088

    RECRUITING

    Grapevine, Texas, 76051, United States

  • Galderma Investigational Site # 7091

    RECRUITING

    Tampa, Florida, 33615-4537, United States

  • Galderma Investigational Site # 8012

    RECRUITING

    Glendale, Maryland, 20769-9182, United States

  • Galderma Investigational Site # 8142

    RECRUITING

    Indianapolis, Indiana, 46250-2041, United States

  • Galderma Investigational Site # 8224

    RECRUITING

    Fremont, California, 94538-1603, United States

  • Galderma Investigational Site # 8238

    RECRUITING

    Dallas, Texas, 75230-5808, United States

  • Galderma Investigational Site # 8282

    RECRUITING

    Mount Kisco, New York, 10549-3035, United States

  • Galderma Investigational Site # 8559

    RECRUITING

    Philadelphia, Pennsylvania, 19103-4738, United States

  • Galderma Investigational Site # 8893

    RECRUITING

    Birmingham, Alabama, 35244, United States

  • Galderma Investigational Tracker Site # 6172

    RECRUITING

    Berlin, 12203, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.